ATAI Life Sciences BV (NYSE: ATAI) — Company Overview, News & Financial Data
ATAI Life Sciences pioneers psychedelic and non-psychedelic compounds for mental health, focusing on innovative treatment development.
ATAI Life Sciences BV
ATAI Life Sciences (NASDAQ:ATAI) is a biotechnology company focused on pioneering the development of psychedelic and non-psychedelic compounds for various mental health conditions. Dedicated to transforming mental healthcare, ATAI explores the therapeutic potential of emerging substances to address unmet needs. The company's diverse portfolio includes projects aimed at developing treatments for conditions like depression, anxiety, and addiction. ATAI emphasizes a science-led approach, leveraging innovative technologies and research to create solutions that could significantly improve patient outcomes in the mental health space.
Snapshot
Operations
Products and/or services of ATAI Life Sciences BV
- Development of a broad portfolio of psychedelic and non-psychedelic compounds for various mental health indications.
- Partnership with Compass Pathways to research and develop psilocybin therapy for treatment-resistant depression.
- Investment in Perception Neuroscience to advance arketamine for psychiatric and neurological disorders.
- Collaboration with DemeRx for the clinical development of ibogaine to treat opioid addiction.
- Launch of IntroSpect Digital Therapeutics, focusing on digital mental health solutions.
- Support for Viridia Life Sciences in developing DMT therapies for mental health conditions.
ATAI Life Sciences BV executive team
- Mr. Christian AngermayerCo-Founder & Chairman of the Board
- Dr. Srinivas G. Rao M.D., Ph.D.Co-Founder, CEO & Executive Director
- Ms. Anne Johnson CPAChief Financial Officer
- Dr. Gerd G. Kochendoerfer Ph.D.Chief Operating Officer
- Dr. Glenn Short Ph.D.Chief Scientific Officer
- Ashleigh BarretoSenior Director of Investor Relations
- Mr. Ryan Barrett J.D.Chief Legal & Business Officer
- Dr. Kevin Craig M.D.Chief Medical Officer
- Dr. Robert Conley M.D.Chief Research & Development Officer
Latest news about ATAI Life Sciences BV
Eli Lilly to acquire AtaiBeckley in $2.8 billion deal
United StatesAtaiBeckley jumps 50% on Lilly takeover report
United StatesAtaiBeckley finishes dosing depression trial patients
United StatesAtaiBeckley extends cash runway to 2029 as key mental health trials advance
United StatesAtaiBeckley reports rapid and durable antidepressant response in Phase 2a trial of BPL-003
United StatesAtaiBeckley jumps as single dose of psychedelic spray sustains depression relief
United States
Key financials
Reported results for ATAI Life Sciences BV, in USD.
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 4.1M | -99.8M | -660M | |
| 308K | -102.7M | -149.3M | |
| 314K | -125.5M | -40.2M | |
| 233K | -144.4M | -152.4M |